Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | VNN1 | O95497 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | MC3R | P41968 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15572500 | 0.98 | KDM4E (0.47) | KDM4ENAPRTHCAR2IDO1KMT2A | |
| Hydrochloric Acid SCHEMBL1373071 | 0.98 | KDM4E (0.47) | KDM4ENAPRTHCAR2IDO1KMT2A | |
| SCHEMBL15571198 | 0.98 | KDM4E (0.47) | KDM4ENAPRTHCAR2IDO1KMT2A | |
| SCHEMBL15572404 | 0.98 | IDO1 (0.48) | KDM4ENAPRTHCAR2IDO1KMT2A | |
| SCHEMBL15571571 | 0.98 | KDM4E (0.47) | KDM4ENAPRTHCAR2IDO1KMT2A | |
| SCHEMBL27567832 | 0.84 | VNN1 (0.43) | KDM4ENAPRTHCAR2IDO1KMT2A | |
| SCHEMBL4086758 | 0.81 | IDO1 (0.44) | KDM4ENAPRTHCAR2IDO1KMT2A | |
| SCHEMBL1483374 | 0.81 | ADORA3 (0.50) | KDM4ENAPRTHCAR2IDO1KMT2A | |
| SCHEMBL30373798 | 0.81 | ADORA3 (0.50) | KDM4ENAPRTHCAR2IDO1KMT2A | |
| SCHEMBL7299189 | 0.81 | IDO1 (0.44) | KDM4ENAPRTHCAR2IDO1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021118485-A1 | A PRODUCTION METHOD OF BIOACTIVE SUBSTANCE THYMOKINONE BY USING AY-YLDIZ CATALYST WHITH USE POTENTIAL IN CANCER TREATMENT | CUKUROVA UNIVERSITESI REKTORLUGU (TR) | 2021-06-17 | — | — | WO | claimed |
| CN-103443099-B | Regulate composition and the method for FXR | NOVARTIS AG (CH) | 2016-03-23 | — | — | CN | claimed |
| CN-103443099-A | Compositions and methods for modulating FXR | IRM LLC | 2013-12-11 | — | — | CN | claimed |
| CN-101312972-B | Bicyclic cinnamide compound | EISAI R&D MAN CO LTD | 2012-06-20 | — | — | CN | claimed |
| EP-1608339-B8 | PHARMACEUTICAL CO-CRYSTAL OF CELECOXIB-NICOTINAMIDE | MCNEIL PPC INC (US) | 2012-04-25 | — | — | EP | claimed |
| CN-101472902-A | Novel piperazine compounds and their use as HCV polymerase inhibitors | JAPAN TOBACCO INC (JP) | 2009-07-01 | — | — | CN | claimed |
| CN-101312972-A | Bicyclic cinnamide compound | EISAI R&D MAN CO LTD (JP) | 2008-11-26 | — | — | CN | claimed |
| US-20070026078-A1 | Pharmaceutical co-crystal compositions | TRANSFORM PHARMACEUTICALS, INC. (US) | 2007-02-01 | — | — | US | claimed |
| EP-1631260-A2 | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS OF DRUGS SUCH AS CARBAMAZEPINE, CELECOXIB, OLANZAPINE, ITRACONAZOLE, TOPIRAMATE, MODAFINIL, 5-FLUOROURACIL, HYDROCHLOROTHAZIDE, ACETAMINOPHEN, ASPIRIN, FLURBIPROFEN, PHENYTOIN AND IBUPROFEN | Transform Pharmaceuticals, Inc. (US) | 2006-03-08 | — | — | EP | claimed |
| EP-1608339-A1 | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS OF DRUGS SUCH AS CARBAMAZEPINE, CELECOXIB, OLANZAPINE, ITRACONAZOLE, TOPIRAMATE, MODAFINIL, 5-FLUOROURACIL, HYDROCHLOROTHIAZIDE, ACETAMINOPHEN, ASPIRIN, FLURBIPROFEN, PHENYTOIN AND IBUPROFEN | Transform Pharmaceuticals, Inc. (US) | 2005-12-28 | — | — | EP | claimed |
| WO-2004078161-A1 | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS OF DRUGS SUCH AS CARBAMAZEPTINE, CELECOXIB, OLANZAPINE, ITRACONAZOLE, TOPIRAMATE, MODAFINIL, 5-FLUOROURACIL, HYDROCHLOROTHIAZIDE, ACETAMINOPHEN, ASPIRIN, FLURBIPROFEN, PHENYTOIN AND IBUPROFEN | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-09-16 | — | — | WO | claimed |
| WO-2004078163-A2 | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS OF DRUGS SUCH AS CARBAMAZEPINE, CELECOXIB, OLANZAPINE, ITRACONAZOLE, TOPIRAMATE, MODAFINIL, 5-FLUOROURACIL, HYDROCHLOROTHIAZIDE, ACETAMINOPHEN, ASPIRIN, FLURBIPROFEN, PHENYTOIN AND IBUPROFEN | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-09-16 | — | — | WO | claimed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4702033-A1 | DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| US-20250326726-A1 | FERROPTOSIS INHIBITORS-PHENOXAZINE ACETAMIDES | SIRONAX BEIJING CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| CN-119866332-A | Iron death inhibitor-phenoxazine acetamides | 维泰瑞隆（北京）生物科技有限公司 | 2025-04-22 | — | — | CN | disclosed |
| EP-0369743-A2 | Heterocyclic amides | ZENECA LIMITED (GB) | 1990-05-23 | — | — | EP | disclosed |
| US-4046763-A | INTERMEDIATE FOR ULTRAVIOLET LIGHT ABSORBERS | MCNEIL LABORATORIES, INCORPORATED (US) | 1977-09-06 | — | — | US | disclosed |
| US-3928347-A | Pyrazinylmalonic acid esters and salts and pyrazinylacetic acids, esters and salts | MCNEILAB INC | 1975-12-23 | — | — | US | disclosed |
| US-3865826-A | Certain derivatives of pyrazinylmalonates and pyrazineacetic acids | MCNEILAB INC | 1975-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326726-A1 | FERROPTOSIS INHIBITORS-PHENOXAZINE ACETAMIDES | AIFM2, GPX4, FECH | KDM4E 3427/4885NAPRT 1878/4885HCAR2 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.